Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (Nasdaq: HYPR) reported strong Q1 2026 results and strategic milestones for its Swoop® portable MR brain imaging system.
- Q1 revenue $3.90M, up 83% YoY; 10 systems sold
- Gross margin 51% vs 41% YoY
- Net loss $8.62M ($0.09/share), narrower YoY
- R&D expenses down 24% to $3.85M
- Secured $15M debt financing, extending expected cash runway into 2028
- Obtained CE Mark and UKCA for next-gen Swoop® and Optive AI™; launched first system in India
- 2026 revenue guidance $20–22M; cash burn guidance $26–28M
Hyperfine (Nasdaq: HYPR) will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 8:45 AM ET. A live audio webcast and archived recording will be available on the company’s Investors page. Management will also hold in-person meetings; scheduling is via Jefferies or the investor contact.
Hyperfine (NASDAQ: HYPR) announced clinical use of the Swoop® portable MRI at All India Institute of Medical Sciences, New Delhi—the first bedside MRI deployed for routine clinical brain imaging in India. Radiosurgery Global is the exclusive distributor; AIIMS will use the system for stroke, ICU, trauma, neonatal, pediatric and neurosurgical care and clinical research.
Hyperfine (Nasdaq: HYPR) will report first-quarter 2026 financial results on Tuesday, May 12, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live audio webcast and archived recording available on the company’s Investors page. Participants should register at least 15 minutes early.
Hyperfine (Nasdaq: HYPR) received CE Marking and UKCA approval for its next-generation Swoop® system and the latest Optive AI™ software, enabling commercialization across the European Economic Area and the United Kingdom.
The next-generation Swoop, FDA-cleared in Q2 2025, delivers improved image quality and workflow; Optive AI adds multi-direction DWI for better small-stroke detection. Commercial launch in Europe and the UK is planned early Q3 2026.
Horizon Technology Finance (NASDAQ: HRZN) provided a $40 million loan facility to Hyperfine (NASDAQ: HYPR), with $15 million funded at closing and up to $25 million available to support future commercial growth. The financing targets expansion of Hyperfine's FDA-cleared Swoop® point-of-care MR brain imaging system across hospitals and offices.
The facility is presented as supporting Hyperfine's commercial scale-up, a second-generation device rollout, and broader adoption of portable neuroimaging in acute and chronic care settings.
Hyperfine (Nasdaq: HYPR) reported Q4 and full-year 2025 results and a business update on March 18, 2026. Q4 revenue was $5.29M (+128% YoY) and full-year revenue was $13.56M. Q4 gross margin improved to 51%. Cash was $35.09M as of Dec 31, 2025.
Company secured equity and debt financing, obtained regulatory clearance in India, received a $3.7M Gates Foundation grant, and provided 2026 guidance of $20–22M revenue with reduced cash burn.
Hyperfine (Nasdaq: HYPR) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET; a live audio webcast and archived recording will be available on the company investor website. Participants are encouraged to register at least 15 minutes early.
Hyperfine (Nasdaq: HYPR) published the largest dataset to date on stroke detection with the Swoop® portable MRI, a prospective multi-center observational study of 95 patients published in Stroke: Vascular and Interventional Neurology. The next-generation Swoop with an advanced multi-directional DWI sequence detected lesions as small as 2.8 mm (0.15 mL), achieved 100% sensitivity and 100% specificity for lesions >1.0 mL, and reduced scan time by approximately 30%. The advanced DWI sequence was recently cleared by the FDA. Systems were provided under sponsored research agreements; the company was not involved in study design, analysis, or publication decisions.
Hyperfine (Nasdaq: HYPR) announced NEURO PMR study results presented January 16, 2026 showing the portable Swoop® MRI (0.064T) has high diagnostic concordance and superior patient experience in outpatient neurology clinics.
In a prospective, multi-center real-world study of 125 patients at two sites, portable MRI showed 92% blinded concordance with standard MRI for detecting intracranial pathology and 98% concordance in unblinded reviews with clinical history. Patients were 4× more likely to choose portable MRI and rated it superior across comfort, anxiety, claustrophobia, noise, and overall satisfaction (p<0.0001). Trained clinic staff operated Swoop without MR technologists, and scans are eligible for reimbursement under existing brain MRI CPT codes after site accreditation.